Print Page | Sign In | Join
RPA Communication with Federal Agencies

RPA communicates with federal agencies on renal policy issues affecting nephrology practitioners. Comment letters on proposed and final rules issued by federal agencies as well as letters to Administration officials are included in this section.

Title Modified Date
RPA Proposal to PTAC for an ESRD Clinical Episode Payment Model July 13, 2017
RPA sign-on letter to President Trump regarding the impact of the proposed federal hiring freeze on the public health and biomedical research workforce
February 27, 2017
RPA Comments on CMS Interim Final Rule with Comment (IFC) entitled “Conditions for Coverage for End-Stage Renal Disease Facilities—Third Party Payment
January 11, 2017
RPA Comments on Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentives Final Rule
December 19, 2016
RPA Response to CMS Request for Information on Inappropriate Steering of Medicare and Medicaid Beneficiaries to Individual Market Plans
September 20, 2016
RPA Comments on 2017 Medicare Fee Schedule Proposed Rule
September 6, 2016
RPA Comments on the 2017 ESRD PPS Proposed Rule Including AKI Policy
August 23, 2016
RPA Response to KECC Request for Information on ESRD Patient Reported Outcomes and Patient Centric Measures
June 30, 2016
RPA Comments on Merit-Based Incentive Payment System (MIPS) and Alternative Payment Model (APM) Incentives Proposed Rule.
June 27, 2016
RPA Comments to ONC Regarding Assessing Interoperability for MACRA
June 3, 2016
RPA Comments on 2016 Medicare Fee Schedule Final Rule December 29, 2015
RPA Response to CMS Request for Information on Medicare Incentive Payment Systems and Alternate Payment Models November 17, 2015
RPA Comments on Draft GAO Report to Congress on Medicare Payment Policies for Home Dialysis November 17, 2015
RPA Comments on 2016 Medicare Fee Schedule Proposed Rule September 08, 2015
RPA Comments on 2016 ESRD QIP Proposed Rule August 25, 2015
RPA Letter to CMS re: Planned Revision of the ESRD Medical Evidence Report - Form 2728 July 08, 2015
RPA Sign-on Letter to Support Medicare Reimbursement of Advance Care Planning Services May 12, 2015
RPA Comments on Conditions for Coverage for ESRD Facilities April 01, 2015
RPA Comments on the 2015 Medicare Fee Schedule Final Rule December 29, 2014
RPA Letter to the Food and Drug Administration on the Peritoneal Dialysis Shortage September 12, 2014
RPA Comments on 2015 Medicare Fee Schedule Proposed Rule September 02, 2014
RPA Comments on 2015 ESRD Prospective Payment System Proposed Rule September 02, 2014
RPA Comments on Dialysis Facility Compare Star Ratings System August 13, 2014
RPA Comments on NCCI Edits Affecting Dialysis and Evaluation and Management Services August 04, 2014
RPA Comments on 2015 Hospice Payment Update July 01, 2014
RPA’s Letter to Patrick Conway, M.D., CMS, on ESCO TEP Measures March 31, 2014
RPA Comments on Medicare Advantage and Prescription Drug Program Proposed Rule March 06, 2014
RPA, Internal Medicine Community Input on Meaningful Use February 03, 2014
RPA Comments on the 2014 Medicare Fee Schedule Final Rule January 27, 2014
RPA Comments on the 2014 Medicare Fee Schedule Proposed Rule September 06, 2013
RPA Comments on the 2013 ESRD Prospective Payment System Proposed Rule August 30, 2013
RPA, Antibiotic Resistance Community Letter to Congress on Advanced Molecular Detection Infectious Disease Outbreaks May 09, 2013
RPA comments on the 30-Day Hospital Readmission Measure and Anemia Management Measures for ESRD Population May 03, 2013
RPA, Kidney Professional Societies’ Comments on ESRD Seamless Care Organizations (ESCOs) May 01, 2013
RPA Comments on 2013 Final Medicare Fee Schedule December 31, 2012
RPA, Stakeholder Group Letter on Kidney Integrated Care Pilot Project October 15, 2012
RPA Letter to CMS on IDPN Availability September 19, 2012
RPA Comments on 2013 Medicare Fee Schedule Proposed Rule September 04, 2012
RPA Comments on Meaningful Use Stage Two Proposed Rule May 07, 2012
RPA, Renal Community Sign-On Letter for NIDDK Funding March 23, 2012
RPA Comments on ESRD Networks Scope of Work (SOW) February 23, 2012
RPA Comments on the 2012 Medicare Fee Schedule Final Rule January 03, 2012
RPA Comments on Changes to the End-Stage Renal Disease Prospective Payment System for 2012 and the End-Stage Renal Disease Quality Incentive Program for PY 2013 and 2014 August 30, 2011
RPA Comments on the 2012 Medicare Physician Fee Schedule Proposed Rule August 30, 2011
RPA Letter to FDA re: ESA Labeling Changes August 17, 2011
RPA Comments on ACO Proposed Rule June 07, 2011
RPA Comments on CMS Program Decision Memorandum on Coverage for ESAs April 18, 2011
RPA Comments on MEDCAC Technical Assessment Regarding ESAs and Renal Transplant Survival February 23, 2011
Dr. Ruben Velez' & RPA’s Written Statement Re: CMS MEDCAC Meeting January 26, 2011
RPA's Comments on 2011 Medicare Fee Schedule Final Rule January 03, 2011
RPA ACO CMS Comment Letter December 03, 2010
RPA Testimony to October 18, 2010 FDA CRDAC Panel Meeting on TREAT Study October 25, 2010
RPA Comments on the ESRD Quality Incentive Program Proposed Rule September 24, 2010
RPA Comments on 2011 Medicare Fee Schedule Proposed Rule August 24, 2010
RPA Letter to FDA re: Risk Evaluation and Mitigation Strategy (REMS) for Erythropoeisis Stimulating Agents (ESAs) July 26, 2010
MEDCAC Statement March 2010 March 25, 2010
Medicare and Medicaid Programs; Electronic Health Record Incentive Program; Proposed Rule March 15, 2010
RPA Guidance on Use of ESAs in CKD March 08, 2010
RPA 2010 Medicare Fee Schedule Comments December 29, 2009
ESRD Bundling Comment December 15, 2009
ESRD Network Redesign Comments December 10, 2009
CDC Comment on Catheter Guidelines December 03, 2009
Medicare Program: Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for CY 2010; Proposed Rule August 31, 2009
Medicare Program: Proposed Revisions to Payment Policies Under the Physician Fee Schedule December 23, 2008
Testimony Presented Before the FDA September 11, 2007
RPA Leaders Address Food and Drug Administration on Safety of Anemia Management Therapies September 01, 2007

Renal Physicians Association

1700 Rockville Pike
Suite 220
Rockville, MD 20852

Phone: 301-468-3515
Fax: 301-468-3511
Email: rpa@renalmd.org

More Info

FAQs